medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2012, Number 3

<< Back Next >>

Arch Neurocien 2012; 17 (3)

Study protocol for a multicentre cohort of Mexican patients with Parkinson’s disease to assess motor, non motor and genetic determinants on the progression

Cervantes-Arriaga A, Rodríguez-Violante M, Zuñiga-Ramírez C, López-Ruiz M, Estrada-Bellman E, Otero-Cerdeira E, Dávila-Ortiz D, Cantú-Brito C

Language: Spanish
References: 30
Page: 159-164
PDF size: 74.25 Kb.


ABSTRACT

Objective: to describe the study design of a prospective cohort to identify the impact of motor, non-motor and genetic factors on the progression and frequency of complications in Mexican patients with Parkinson’s disease. Methods: the design, calculation of sample size, primary and secondary objectives, recruitment strategy, clinimetric scales to apply and its justification, genetic studies and ethical implications of the study protocol are promptly described. Results: Between January and December of 2011 several preliminary studies were carried out to assess the feasibility and identify technical and methodological issues. During this stage, preliminary information of 773 patients with Parkinson’s disease was captures. Conclusions: The multicenteric cohort study will provide valuable information on motor, non-motor and genetic factors specific to Mexican population and its impact on disease progression.


REFERENCES

  1. Van Den Eeden SK, Tanner CM, Bernstein AL. Incidence of Parkinson’s Disease: variation by age, gender, and race/ ethnicity. Am J Epidemiol 2003;157: 1015-22.

  2. Bohlhalter S, Kaegi G. Parkinsonism: heterogeneity of a common neurological síndrome. Swiss Med Wkly 2011; doi: 10.4414/smw.

  3. Whone AL, Watts RL, Stoessl AJ. Slower progression of Parkinson´s disease with ropinirole versus levodopa: the Realpet study. Ann Neurol 2003; 54:93-101.

  4. Tabachnick BG, Fidell LS: Multiple regression New York: Harper Collins College Publications. 1996.

  5. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.

  6. Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martínez- Martín P, Bonuccelli U, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatr y 2004; 75:388-95

  7. Chaudhuri KR, Martínez-Martin P, Brown RG, Sethi K, Stocchi F. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Result from an international pilot study. Mov Disord 2007; 13: 1901-11.

  8. Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, López-Gómez M, Corona T. Metric properties of clinimetric indexes for non-motor dysfunction of Parkinson’s disease in Mexican population. Rev Invest Clin 2010; 62:8-14.

  9. Dalrymple-Alford JC, MacAskill MR, Nakas CT. The MoCA: Wellsuited screen for cognitive impairment in Parkinson disease. Neurol 2010;75:1717-25.

  10. Martínez-Martín P, Visser M, Rodríguez-Blazquez C, Marinus J, Chaudhuri KR, van Hilten JJ. SCOPA-Sleep and PDSS. Two scales for assessement of sleep disorder in Parkinson’s disease. Mov Disord 2008; 23:1681-8.

  11. Cervantes-Arriaga A, Rodríguez-Violante M, Velez-Cedeño A, Alatriste-Booth V. Estudio piloto de validación de la escala de SCOPA-sueño en pacientes mexicanos con enfermedad de Parkinson. Rev Mex Neuroci 2011; 12:346-51.

  12. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire. Psychol Health 1997; 12: 805-14.

  13. Schrag A, Barone P, Brown RG, Leentjens AFG, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov disor 2007; 22;1077-92.

  14. Rodríguez-Violante M, Ramírez-Valadez C, Mathieu Betancour R, López-Ruiz M, Cervantes-Arriaga A, Morales-Briceño H. Características clínicas y fenotipo motor de pacientes mexicanos con enfermedad de Parkinson de tres centros de referencia de la ciudad de México. Rev Mex Neurosci 2011; 288.

  15. Rodríguez-Violante M, López-Ruíz M, Cer vantes-Arriaga A, Morales-Briceño H. Estudio piloto de la implementación de la escala corta de evaluación de la enfermedad de Parkinson (SPES/SCOPA) en pacientes de dos centros de referencia de la Ciudad de México. Rev Mex Neurosci 2011; 12:386.

  16. Van Den Eeden SK, Tanner CM, Bernstein AL. Incidence of Parkinson’s Disease: variation by age, gender, and race/ ethnicity. Am J Epidemiol 2003;157: 1015-22.

  17. Bohlhalter S, Kaegi G. Parkinsonism: heterogeneity of a common neurological síndrome. Swiss Med Wkly 2011; doi: 10.4414/smw.

  18. Whone AL, Watts RL, Stoessl AJ. Slower progression of Parkinson´s disease with ropinirole versus levodopa: the Realpet study. Ann Neurol 2003; 54:93-101.

  19. Tabachnick BG, Fidell LS: Multiple regression New York: Harper Collins College Publications. 1996.

  20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.

  21. Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martínez- Martín P, Bonuccelli U, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatr y 2004; 75:388-95

  22. Chaudhuri KR, Martínez-Martin P, Brown RG, Sethi K, Stocchi F. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Result from an international pilot study. Mov Disord 2007; 13: 1901-11.

  23. Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, López-Gómez M, Corona T. Metric properties of clinimetric indexes for non-motor dysfunction of Parkinson’s disease in Mexican population. Rev Invest Clin 2010; 62:8-14.

  24. Dalrymple-Alford JC, MacAskill MR, Nakas CT. The MoCA: Wellsuited screen for cognitive impairment in Parkinson disease. Neurol 2010;75:1717-25.

  25. Martínez-Martín P, Visser M, Rodríguez-Blazquez C, Marinus J, Chaudhuri KR, van Hilten JJ. SCOPA-Sleep and PDSS. Two scales for assessement of sleep disorder in Parkinson’s disease. Mov Disord 2008; 23:1681-8.

  26. Cervantes-Arriaga A, Rodríguez-Violante M, Velez-Cedeño A, Alatriste-Booth V. Estudio piloto de validación de la escala de SCOPA-sueño en pacientes mexicanos con enfermedad de Parkinson. Rev Mex Neuroci 2011; 12:346-51.

  27. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson’s disease questionnaire. Psychol Health 1997; 12: 805-14.

  28. Schrag A, Barone P, Brown RG, Leentjens AFG, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov disor 2007; 22;1077-92.

  29. Rodríguez-Violante M, Ramírez-Valadez C, Mathieu Betancour R, López-Ruiz M, Cervantes-Arriaga A, Morales-Briceño H. Características clínicas y fenotipo motor de pacientes mexicanos con enfermedad de Parkinson de tres centros de referencia de la ciudad de México. Rev Mex Neurosci 2011; 288.

  30. Rodríguez-Violante M, López-Ruíz M, Cer vantes-Arriaga A, Morales-Briceño H. Estudio piloto de la implementación de la escala corta de evaluación de la enfermedad de Parkinson (SPES/SCOPA) en pacientes de dos centros de referencia de la Ciudad de México. Rev Mex Neurosci 2011; 12:386.




2020     |     www.medigraphic.com